On October 22, Twist Bioscience Corp fell 5.1% Overnight to $141.53 per share, with turnover of $1.33 million.
The latest publicly discussed catalyst remained a previously disclosed position change statement involving Laponis Adam, which has continued to drive attention and volatility in the stock.
Recent market coverage showed the same event had already triggered sharp swings, including a 5.4% pre-market drop and a 5.16% move higher during regular trading on October 21. Analyst views also remained mixed, with Jefferies initiating at Hold with a $150 price target and UBS initiating at Neutral with a $144 price target, underscoring ongoing debate over near-term valuation.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments